These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Lichtenstein JR Arthritis Rheum; 2003 Jan; 48(1):282-3; author reply 283. PubMed ID: 12528146 [No Abstract] [Full Text] [Related]
6. [Calcium antagonists in the treatment of Raynaud's syndrome and in the treatment of esophageal spasm]. Kahan A; Amor B; Menkès CJ Rev Prat; 1988 Nov; 38(27):1986-8. PubMed ID: 3206151 [No Abstract] [Full Text] [Related]
7. Advances in the treatment of Raynaud's phenomenon. Levien TL Vasc Health Risk Manag; 2010 Mar; 6():167-77. PubMed ID: 20448801 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors in Raynaud's phenomenon. Levien TL Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313 [TBL] [Abstract][Full Text] [Related]
9. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Kamata Y; Kamimura T; Iwamoto M; Minota S Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103 [No Abstract] [Full Text] [Related]
10. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Gore J; Silver R Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356 [No Abstract] [Full Text] [Related]
11. Viagra and health: beyond ED. Harv Mens Health Watch; 2007 Aug; 12(1):1-4. PubMed ID: 18018319 [No Abstract] [Full Text] [Related]
12. [Treatment of Raynaud's phenomenon]. Lazareth I Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456 [No Abstract] [Full Text] [Related]
13. [Improvement of idiopathic Raynaud's phenomenon following local infusion of botulinum toxin]. Roguedas AM; Misery L Ann Dermatol Venereol; 2014; 141(6-7):462-3. PubMed ID: 24951147 [No Abstract] [Full Text] [Related]
14. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of Raynaud's syndrome with calcium entry blockers]. Shcherbakov AB; Guseva NG; Mach ES Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288 [TBL] [Abstract][Full Text] [Related]
16. [Medical treatment of the Raynaud phenomenon]. Zicot M Phlebologie; 1987; 40(1):47-9. PubMed ID: 3033711 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists]. Shcherbakov AB Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706 [TBL] [Abstract][Full Text] [Related]
18. Calcium channel blockers and Raynaud's disease. Vayssairat M; Capron L; Fiessinger JN; Mathieu JF; Housset E Ann Intern Med; 1981 Aug; 95(2):243. PubMed ID: 6266305 [No Abstract] [Full Text] [Related]
19. [Management of Raynaud's phenomenon]. Boccalon H; Monin A; Reggy M Soins Cardiol; 1986 Apr; (38):27-9. PubMed ID: 3637023 [No Abstract] [Full Text] [Related]
20. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Thompson AE; Shea B; Welch V; Fenlon D; Pope JE Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]